Welcome to our dedicated page for GSK PLC news (Ticker: GSK), a resource for investors and traders seeking the latest updates and insights on GSK PLC stock.
GSK PLC (GSK) is a global leader in pharmaceuticals and vaccines, driving innovation in respiratory health, oncology, and infectious disease treatments. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments shaping the healthcare landscape.
Track all essential announcement through curated press releases, earnings reports, and regulatory filings. Our repository covers clinical trial milestones, strategic partnerships, and product pipeline updates while maintaining strict compliance with financial disclosure standards.
Key focus areas include advancements in vaccine research, therapeutic innovations, and global health initiatives. The organized format enables quick scanning of market-moving developments while preserving depth for fundamental analysis.
Bookmark this page for direct access to GSK's official communications and third-party analysis verification. Regular updates ensure you stay informed about this FTSE 100 constituent's operational and financial trajectory without promotional bias.
GSK plc (LSE/NYSE: GSK) has announced its agreement to acquire BELLUS Health Inc. (TSX/NASDAQ: BLU) for US$14.75 per share, totaling an approximate equity value of US$2.0 billion. This acquisition aims to strengthen GSK's specialty medicines and respiratory pipeline, particularly through camlipixant, a selective P2X3 antagonist for refractory chronic cough (RCC), currently in phase III clinical trials with a launch anticipated in 2026. The deal is projected to be accretive to adjusted EPS starting from 2027 and has significant sales potential through 2031.
With an estimated 28 million patients suffering from chronic cough globally, this acquisition addresses a substantial unmet medical need, as no approved medicines currently exist for RCC in the US and EU.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has achieved a $30 million milestone from GSK (LSE/NYSE: GSK) following the initiation of GSK4532990's Phase 2b trial for treating non-alcoholic steatohepatitis (NASH). This investigational RNA interference therapeutic was licensed to GSK in November 2021, with Arrowhead retaining rights for Greater China. The trial, known as HORIZON (NCT05583344), will assess the drug's efficacy and safety in up to 246 participants with pre-cirrhotic NASH. GSK4532990 targets HSD17B13, a gene linked to metabolic protection against NASH.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
